Rising Stars in running for new Gypsy Vanner therapy horse
Click on the button below to set up your account or log in if you already have one. Already a subscriber?
New drug therapy could improve brain function and life expectancy of ALS patients: Researcher redesigned a portion of FDA-approved MabThera into a new molecule to treat ALS -- ScienceDaily
She successfully redesigned a portion of MabThera, an FDA-approved drug used to treat certain autoimmune diseases and types of cancer, into a new molecule to treat ALS. "We found a way to thwart the glial cells from attacking and killing healthy brain cells," says Dr. Lichtenstein. "Our experimental results on ALS transgenic mice showed a significant increase in life expectancy," says Dr. Lichtenstein. Since the exact cause of ALS is unknown, current research has focused on extending the post-onset life expectancy, which is currently between two to five years for most patients. ALS, also known as Lou Gehrig's disease, is a lethal, progressive neurodegenerative disorder that affects the motor nerve cells in both the brain and the spinal cord.collected by :Lucy William
No comments:
Post a Comment